Bordetella pertussis seroprevalence in Belgian adults aged 20-39 years, 2012

被引:26
作者
Huygen, K. [1 ]
Rodeghiero, C. [1 ]
Govaerts, D. [2 ]
Leroux-Roels, I. [3 ]
Melin, P. [4 ]
Reynders, M. [5 ]
Van der Meeren, S. [6 ]
Van den Wijngaert, S. [7 ]
Pierard, D. [6 ]
机构
[1] WIV ISP, Brussels, Belgium
[2] CHU Charleroi, Charleroi, Belgium
[3] UZ Gent, Ghent, Belgium
[4] CHU Liege, Liege, Belgium
[5] Acad Hosp St Jan, Brugge, Belgium
[6] UZ Brussel, Brussels, Belgium
[7] CHU St Pierre, Brussels, Belgium
关键词
Pertussis (whooping cough); vaccine-preventable diseases; VACCINATION; INFECTION;
D O I
10.1017/S0950268813002458
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The last report on pertussis seroprevalence in Belgium concerned samples collected during 1993-1994. In the context of the Eupert-Labnet WP6 seroprevalence study (comparing sera from 16 European member states), 1500 anonymized leftover diagnostic samples were collected randomly during the second semester of 2012 by the clinical chemistry laboratories of six participating Belgian centres, distributed equally between Flanders, Wallonia and Brussels Capital Region. As suggested by the WP6 organizers, a total of 750 samples (125/centre) were selected from subjects in the 20-29 years age group and 750 samples (125/centre) from subjects in the 30-39 years age group. Anti-PT IgG levels were measured using Virion-Serion ELISA and analysed using predefined cut-off levels. Sixty-one (4%) sera were indicative of an infection in the past 2 years (between 50 and 100 IU/ml) and another 61 (4%) sera had anti-PT IgG antibodies reflecting acute infection (> 100 IU/ml). These results highlight the presence of a Bordetella pertussis reservoir in the adult 'healthy' Belgian population.
引用
收藏
页码:724 / 728
页数:5
相关论文
共 14 条
[1]   Pertussis:: increasing disease as a consequence of reducing transmission [J].
Aguas, R ;
Gonçalves, G ;
Gomes, MGM .
LANCET INFECTIOUS DISEASES, 2006, 6 (02) :112-117
[2]   Seroprevalence of Pertussis in the Netherlands: Evidence for Increased Circulation of Bordetella pertussis [J].
de Greeff, Sabine C. ;
de Melker, Hester E. ;
van Gageldonk, Pieter G. M. ;
Schellekens, Joop F. P. ;
van der Klis, Fiona R. M. ;
Mollema, Liesbeth ;
Mooi, Frits R. ;
Berbers, Guy A. M. .
PLOS ONE, 2010, 5 (12)
[3]   Vaccinate the Village [J].
DeMaria, Alfred, Jr. ;
Lett, Susan M. .
CLINICAL INFECTIOUS DISEASES, 2010, 50 (10) :1346-1348
[4]   New pertussis vaccination strategies beyond infancy:: Recommendations by the global pertussis initiative [J].
Forsyth, KD ;
Campins-Marti, M ;
Caro, J ;
Cherry, JD ;
Greenberg, D ;
Guiso, N ;
Heininger, U ;
Schellekens, J ;
Tan, T ;
von König, CHW ;
Plotkin, S .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (12) :1802-1809
[5]   Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children [J].
Hallander, Hans O. ;
Ljungman, Margaretha ;
Storsaeter, Jann ;
Gustafsson, Lennart .
APMIS, 2009, 117 (11) :797-807
[6]   IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: Effect of vaccine antigen content [J].
Hendrikx, Lotte H. ;
Berbers, Guy A. M. ;
Veenhoven, Reinier H. ;
Sanders, Elisabeth A. M. ;
Buisman, Anne-Marie .
VACCINE, 2009, 27 (47) :6530-6536
[7]  
Munoz FM, 2013, PEDIATR ANN, V42, P153, DOI [10.3928/00904481-20130723-09, 10.3928/00904481-20130723]
[8]   Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine [J].
Olin, P ;
Rasmussen, F ;
Gustafsson, L ;
Hallander, HO ;
Heijbel, H .
LANCET, 1997, 350 (9091) :1569-1577
[9]   Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium [J].
Theeten, H. ;
Hutse, V. ;
Hens, N. ;
Yavuz, Y. ;
Hoppenbrouwers, K. ;
Beutels, P. ;
Vranckx, R. ;
Van Damme, P. .
EPIDEMIOLOGY AND INFECTION, 2011, 139 (04) :494-504
[10]   Seroprevalence of Bordetella pertussis antibodies in Flanders (Belgium) [J].
Van der Wielen, M ;
Van Damme, P ;
Van Herck, K ;
Schlegel-Haueter, S ;
Siegrist, CA .
VACCINE, 2003, 21 (19-20) :2412-2417